Laboratory Studies for Post-COVID-19 Patient with GI Symptoms and Steatorrhea
Order comprehensive liver function tests (AST, ALT, bilirubin), fecal elastase or fecal fat quantification for pancreatic insufficiency, lipase/amylase, serum IgE and tryptase for urticaria evaluation, and fat-soluble vitamin levels (A, D, E, K) given the steatorrhea presentation.
Prioritized Laboratory Workup
Hepatobiliary Assessment
The AGA guidelines emphasize that abnormal liver function tests occur in approximately 15% of COVID-19 patients and recommend checking baseline LFTs in all patients, particularly those with GI symptoms 1. Specifically order:
- AST and ALT: Elevated in 15% of COVID-19 patients; abnormal LFTs at admission associate with higher risk for severe disease (OR 2.73) 1
- Total, direct, and indirect bilirubin: Abnormal in 16.7% of patients 1
- Alkaline phosphatase and GGT: Recent evidence shows elevated GGT associates with poor prognosis and mortality in COVID-19 patients 2
The guidelines specifically note that abnormal LFTs warrant evaluation to investigate non-COVID causes of liver disease 1.
Pancreatic Function Studies
Given the pale, steatorrheic stools, pancreatic insufficiency must be evaluated:
- Fecal elastase-1 or 72-hour fecal fat quantification: Direct assessment of fat malabsorption
- Lipase and amylase: Elevated amylase levels significantly associate with poor prognosis and mortality in COVID-19 2
Nutritional and Metabolic Markers
Recent research identifies specific deficiencies in post-COVID patients with GI symptoms 3:
- Albumin and pre-albumin: Monitoring these serves as valuable prognosticators; increases correlate with disease severity 3
- Transferrin: Significant increases noted in COVID-19 patients with GI impairments 3
- Fat-soluble vitamins (A, D, E, K): Vitamin K shows significant increases while vitamin D decreases modestly associate with clinical picture 3
- Vitamin B12: Significant decreases documented 3
- Magnesium and calcium: Significant magnesium decrease noted; magnesium-to-calcium ratio may serve as prognosticator 3
Urticaria-Specific Testing
For the urticaria presentation:
- Serum IgE and tryptase: Rule out mast cell activation
- Complete blood count with differential: Assess for eosinophilia
Inflammatory Markers
- C-reactive protein: Important marker for diagnosis and prognosis 4
- Ferritin: Elevated levels (mean 351.5 ng/mL in post-COVID GI patients) significantly associate with poor outcomes, macrophage activation syndrome, critical illness, and mortality 5, 4, 2
- ESR: Important diagnostic and prognostic marker 4
- D-dimer: Abnormalities present to varying extents; important for prognosis 4
Additional Considerations
- Prothrombin time: Post-recovery changes include increased PT in 25.8% of patients 4
- Complete metabolic panel: Screen for new-onset diabetes (0.64% develop primary type 2 DM post-COVID) and electrolyte abnormalities 4
Clinical Context
Common pitfall: The guidelines note that many studies failed to report baseline LFT status before infection 1. Therefore, interpret current values cautiously without prior baseline, and consider that abnormalities may reflect secondary effects (systemic inflammatory response, cytokine storm, drug hepatotoxicity) rather than primary viral injury 1.
Important caveat: Post-COVID persisting symptoms occur in 21.4% of symptomatic patients and significantly relate to illness duration and existing comorbidities 4. The combination of nausea, vomiting, urticaria, and steatorrhea warrants comprehensive evaluation as GI symptoms associate with longer illness duration 1.
The meta-analysis demonstrates that COVID-19 patients with GI symptoms show elevated ALT (pooled MD 4.5 U/L) with trends toward lymphopenia, neutrophilia, and thrombocytopenia 6. Monitor complete blood count accordingly.